ReviewCancers2018
Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum.
Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- A systematic review of progress toward unlocking the power of epigenetics in breast cancer: latest updates and perspectives.Frontiers in pharmacology · 2025Pooled it
- Diagnostic value of combination of biomarkers for malignant pleural mesothelioma: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- LncRNA MIR22HG and miR-10a-5p: Pioneering serum biomarkers for pancreatic cancer diagnosis and progression assessment.Non-coding RNA research · 2026Article
- Epigenetic Biomarkers for Predicting Nucleoside Analog Drug Response and Resistance in Cancer.Biomolecules · 2026Review
- Profiling histone post-translational modifications to identify signatures of epigenetic drug response in T-cell acute lymphoblastic leukemia.Scientific reports · 2026Article
- AI-enabled multi-omics integration in colorectal cancer: from molecular stratification to clinical translation.Frontiers in cell and developmental biology · 2026Review
- Epigenomic landscape of nasopharyngeal carcinoma.Medical oncology (Northwood, London, England) · 2025Review
- Pathogenomic fingerprinting to identify associations between tumor morphology and epigenetic states.European journal of cancer (Oxford, England : 1990) · 2025Article
- Evaluation of silica spin‑column and magnetic bead formats for rapid DNA methylation analysis in clinical and point‑of‑care settings.Biomedical reports · 2024Article
- Article
- Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.Frontiers in immunology · 2024Review
- Ginsenosides: changing the basic hallmarks of cancer cells to achieve the purpose of treating breast cancer.Chinese medicine · 2023Review
- MicroRNAs and long non-coding RNAs in pancreatic cancer: From epigenetics to potential clinical applications.Translational oncology · 2023Article
- [Extraction and isolation of histones from paraffin-embedded tissues and quantitative analysis of post-translational modifications].Se pu = Chinese journal of chromatography · 2021Article
- Article
- The link among microbiota, epigenetics, and disease development.Environmental science and pollution research international · 2021Review
- DNA methylation signature on phosphatidylethanol, not on self-reported alcohol consumption, predicts hazardous alcohol consumption in two distinct populations.Molecular psychiatry · 2021Article
- Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer.Gastroenterology · 2021Review
- CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.Clinical epigenetics · 2021Article
- Maternal high-fat diet increases vascular contractility in adult offspring in a sex-dependent manner.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant epigenetic modifications are an early event in carcinogenesis, with the epigenetic landscape continuing to change during tumor progression and metastasis-these observations suggest that specific epigenetic modifications could be used as diagnostic and prognostic biomarkers for many cancer types. DNA methylation, post-translational histone modifications, and non-coding RNAs are all dysregulated in cancer and are detectable to various degrees in liquid biopsies such as sputum, urine, stool, and blood. Here, we will focus on the application of liquid biopsies, as opposed to tissue biopsies, because of their potential as non-invasive diagnostic tools and possible use in monitoring therapy response and progression to metastatic disease. This includes a discussion of septin-9 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.